Please assess the completion status of the following clinical trial:

Trial Title: Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have confirmed mantle cell lymphoma diagnosis.~* Have measurable disease.~* Have received at least 2 prior treatment, which may include stem cell transplant.~* Have adequate organ and bone marrow function.~* There are other criteria--please discuss with your doctor.~Exclusion Criteria:~* Had any prior treatment with temsirolimus or mTOR inhibitor.~* Had allogeneic stem cell transplant within last 6 months and on immunosuppressive therapy.~* Has active or untreated brain or central nervous system metastases.~* There are other criteria--please discuss with your doctor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- temsirolimus (Torisel) 175mg weekly x 3, then 75mg weekly (Type: ACTIVE_COMPARATOR): None
- temsirolimus (Torisel) 75mg weekly (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).